Olanzapine improves chorea inpatients with Huntington's disease

被引：8

作者：

Jiménez-Jiménez, FJ ^{[1
]}

de Toledo, M ^{[1
]}

Puertas, I ^{[1
]}

Barón, M ^{[1
]}

Zurdo, M ^{[1
]}

Barcenilla, B ^{[1
]}

机构：

[1] Univ Alcala de Henares, Hosp Principe Asturias, Serv Neurol, Madrid, Spain

来源：

REVISTA DE NEUROLOGIA | 2002年 / 35卷 / 06期

关键词：

chorea; Huntington's disease; olanzapine;

D O I：

10.33588/rn.3506.2002159

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Introduction. The main treatment for choreatic movements associated to Huntington's disease are the neuroleptic drugs, however, its use causes long-term troubles. Case reports. We describe two patients with a predominantly choreic Huntington's disease, who experience improvement of choreatic movements after introduction of olanzapine to their treatment, being this drug well tolerated. Conclusions. The improvement of chorea suggests that olanzapine has a dopaminergic D-2 receptors blocking action.

引用

页码：524 / 525

页数：2

共 10 条

[1] High-dose olanzapine in Huntington's disease [J].

Bonelli, RM ;

Niederwieser, G ;

Tribl, GG ;

Költringer, P .

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2002, 17 (02) :91-93

[2] Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha(1)-adrenergic and muscarinic receptors in vivo in rats [J].

Bymaster, FP ;

HemrickLuecke, SK ;

Perry, KW ;

Fuller, RW .

PSYCHOPHARMACOLOGY, 1996, 124 (1-2) :87-94

[3] Olanzapine can worsen parkinsonism [J].

Jiménez-Jiménez, FJ ;

Tallón-Barranco, A ;

Ortí-Pareja, M ;

Zurdo, M ;

Porta, J ;

Molina, JA .

NEUROLOGY, 1998, 50 (04) :1183-1184

[4]

MARSHALL FJ, 1997, MOVEMENT DISORDERS N, P491

[5]

MOLHO ES, 1998, MOV DISORD S2, V13, P256

[6] Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject [J].

O'Brien, J ;

Barber, R .

BRITISH JOURNAL OF PSYCHIATRY, 1998, 172 :186-186

[7] Dopamine D-2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine - A I-123 IBZM single photon emission tomography (SPET) study [J].

Pilowsky, LS ;

Busatto, GF ;

Taylor, M ;

Costa, DC ;

Sharma, T ;

Sigmundsson, T ;

Ell, PJ ;

Nohria, V ;

Kerwin, RW .

PSYCHOPHARMACOLOGY, 1996, 124 (1-2) :148-153

[8]

Safirstein B, 1999, MOVEMENT DISORD, V14, P532, DOI 10.1002/1531-8257(199905)14:3<532::AID-MDS1031>3.0.CO

[9]

2-3

[10] Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease [J].

Wolters, EC ;

Jansen, ENH ;

TuynmanQua, HG ;

Bergmans, PLM .

NEUROLOGY, 1996, 47 (04) :1085-1087

← 1 →